Clinical advances in hematology & oncology : H&O最新文献_第4页

Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. 肿瘤内科患者的癌症类型、癌症治疗和静脉血栓栓塞之间的关系。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

Michael B Streiff

{"title":"Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients.","authors":"Michael B Streiff","doi":"","DOIUrl":"","url":null,"abstract":"Nearly 20% of all venous thromboembolism (VTE) occurs in cancer patients, and as many as 78% of cancer patients who develop a thrombotic event do so as outpatients. The risk of VTE in cancer patients is influenced by the type of cancer, its stage and histology, the presence of thrombophilia, and the many therapeutic interventions they receive (eg, surgery, chemotherapy, radiotherapy, supportive care). The greatest VTE risk appears to occur early after cancer diagnosis and in patients with late- or metastatic-stage malignancy. VTE most often occurs in cancers of the pancreas, ovary, kidney, lung, stomach, and brain, as well as in hematologic malignancies such as lymphoma and myeloma. The clinical consequences of thrombosis in cancer patients are typically more severe and more costly than events in patients without cancer. Patient-, cancer-, and treatment-related factors should be considered when assessing individual patients for their risk of VTE. Primary pharmacologic VTE prophylaxis should be given to all hospitalized medical and surgical oncology patients at risk, and this therapy should be considered for high-risk ambulatory outpatients (eg, myeloma patients receiving highly thrombogenic chemotherapeutic regimens, very-high-risk solid tumor patients with Khorana scores ≥3) who have no contraindications to anticoagulants. ","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"349-57"},"PeriodicalIF":1.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32070572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New targets for hematologic malignancies. 血液恶性肿瘤的新靶点。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

James Bradner

引用次数: 0

Bisphosphonates in colorectal cancer. 结直肠癌中的双膦酸盐。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

Paul J Limburg, Siddharth Singh

引用次数: 0

B-cell receptor inhibitors in chronic lymphocytic leukemia. 慢性淋巴细胞白血病中的b细胞受体抑制剂。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

Jennifer R Brown

引用次数: 0

Managing breast cancer in the older patient. 老年乳腺癌患者的治疗。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

Tracey O'Connor, Arvind Shinde, Caroline Doan, Vani Katheria, Arti Hurria

{"title":"Managing breast cancer in the older patient.","authors":"Tracey O'Connor, Arvind Shinde, Caroline Doan, Vani Katheria, Arti Hurria","doi":"","DOIUrl":"","url":null,"abstract":"Breast cancer is a disease that is associated with aging, with almost one-half of all new breast cancer cases diagnosed annually in the United States occurring in women ages 65 and older. Recent data suggest that although breast cancer outcomes in younger women have shown substantial improvement as a result of advances in treatment and screening, the benefits in older women have been less pronounced. Although older patients have been underrepresented in cancer clinical trials, there is an emerging body of literature to help guide treatment decisions. For early-stage breast cancer, the discussion regarding treatment options involves balancing the reduction in risk of recurrence gained by specific therapies with the potential for increased treatment-related toxicity, potentially exacerbated by physiological decline or comorbidities that often co-exist in the older population. A key component of care is the recognition that chronologic age alone cannot guide the management of an older patient with breast cancer. Rather, treatment decisions must also take into account a patient's functional status, estimated life expectancy, the risks and benefits of the therapy, potential barriers to treatment, and patient preference. This article reviews the available evidence for therapeutic management of early-stage breast cancer in older patients, and highlights data from the geriatric oncology literature that provide a basis on which to facilitate evidence-based treatment. ","PeriodicalId":520589,"journal":{"name":"Clinical advances in hematology & oncology : H&O","volume":" ","pages":"341-7"},"PeriodicalIF":1.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906632/pdf/nihms514556.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32068425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atheists don’t have no songs. 无神论者没有歌。

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

Bruce D Cheson

引用次数: 0

Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma. brentuximab vedotin治疗transplant-naïve复发性cd30阳性结节淋巴细胞主导型霍奇金淋巴瘤患者的完全缓解

IF 1

Clinical advances in hematology & oncology : H&O Pub Date : 2013-06-01

Ciara C O'Sullivan, Metin Ozdemirli, Michael Bazylewicz, Bruce D Cheson

引用次数: 0

Unusual presentation of bladder myeloid sarcoma causing acute renal failure: case report and review of the literature. 膀胱髓样肉瘤引起急性肾功能衰竭的异常表现:病例报告及文献复习。